Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Publication year range
2.
Hum Pathol ; 44(1): 20-8, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22939961

ABSTRACT

The origin of the primary tumor is sometimes difficult to determine in peritoneal and ovarian metastases. A series of 25 metastatic tumors to the ovary and 7 cases of peritoneal carcinomatosis of suspected gynecologic origin were collected. Total RNA was extracted from frozen tumor tissue and studied by the Tissue of Origin-Frozen test, a microarray-based gene expression test from Pathwork Diagnostics (Redwood City, CA). Independently, formalin-fixed, paraffin-embedded tumor tissue was subjected to pathologic analysis. Immunohistochemical stains included keratins 7 and 20, estrogen and progesterone receptors, CDX2, villin, CEA, WT-1, TTF-1, mammoglobin, GCDF-15, and CD31. Clinical data were considered as gold standard, and after clinicopathologic evaluation, the tissue of origin was found in 29 cases. The Tissue of Origin-Frozen test correctly identified the ovary as site of origin in 7 of 7 peritoneal carcinomatosis cases, whereas immunohistochemical stains only allowed appropriate recognition in 5. In addition, the Tissue of Origin-Frozen test identified correctly the site of origin in 18 of the 22 metastatic tumors to the ovary with known origin. In the remaining 4 tumors, the correct origin was the second option in 2 cases and was not determined in the other 2. Immunohistochemistry correctly identified the site of origin in 17 of these 22 ovarian metastases. A combination of Tissue of Origin-Frozen and immunohistochemistry correctly identified the site of origin in 19 of 22 ovarian metastases of known origin. Although conventional pathologic examination and immunohistochemistry are commonly used for assessing the tumor site of origin, Tissue of Origin testing can be useful in difficult cases.


Subject(s)
Gene Expression Regulation, Neoplastic/genetics , Neoplasms, Multiple Primary/genetics , Neoplasms, Multiple Primary/secondary , Ovarian Neoplasms/genetics , Ovarian Neoplasms/secondary , Peritoneal Neoplasms/secondary , Biomarkers, Tumor/genetics , Female , Humans , Immunohistochemistry , Neoplasms, Multiple Primary/pathology , Oligonucleotide Array Sequence Analysis , Ovarian Neoplasms/pathology , Peritoneal Neoplasms/genetics , Peritoneal Neoplasms/pathology , Reproducibility of Results , Retrospective Studies
3.
Endocr Relat Cancer ; 17(1): 7-16, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19776290

ABSTRACT

Therapeutic options for patients with metastatic medullary thyroid carcinoma (MTC) are limited due to lack of effective treatments. Thus, there is a need to thoroughly characterize the pathways of molecular pathogenesis and to identify potential targets for therapy in MTC. Since epidermal growth factor receptor (EGFR) seems to play a crucial role for RET activation, a key feature of MTCs, and several promising EGFR/vascular endothelial growth factor receptor 2 (VEGFR2)-targeted drugs have been developed, the present study was designed to investigate whether these proteins are altered in MTCs. We used a well-characterized series of 153 MTCs to evaluate EGFR activation by sequencing and FISH analysis, and to perform EGFR and VEGFR2 immunohistochemistry. EGFR tyrosine kinase domain mutations were not a feature of MTCs; however, EGFR polysomy and a strong EGFR expression were detected in 15 and 13% of the tumors respectively. Interestingly, EGFR was significantly overexpressed in metastases compared with primary tumors (35 vs 9%, P=0.002). We also studied whether specific RET mutations were associated with EGFR status, and found a decrease in EGFR polysomies (P=0.006) and a tendency towards lower EGFR expression for the most aggressive RET mutations (918, 883). Concerning VEGFR2, metastasis showed a higher expression than primary tumors (P=2.8 x 10(-8)). In this first study investigating the relationship between EGFR, RET, and VEGFR2 in a large MTC series, we found an activation of EGFR and VEGFR2 in metastasis, using both independent and matched primary/metastasis samples. This suggests that some MTC patients may benefit from existing anti-EGFR/VEFGR2 therapies, although additional preclinical and clinical evidence is needed.


Subject(s)
Carcinoma, Medullary/secondary , ErbB Receptors/biosynthesis , Gene Expression Regulation, Neoplastic , Neoplasm Proteins/physiology , Thyroid Neoplasms/metabolism , Vascular Endothelial Growth Factor Receptor-2/biosynthesis , Adolescent , Adult , Aged , Aged, 80 and over , Aneuploidy , Carcinoma, Medullary/genetics , Carcinoma, Medullary/metabolism , Carcinoma, Medullary/pathology , Chromosomes, Human, Pair 7/genetics , ErbB Receptors/physiology , Female , Gene Amplification , Gene Dosage , Genes, erbB-1 , Humans , In Situ Hybridization, Fluorescence , Male , Middle Aged , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Proto-Oncogene Proteins c-ret/genetics , Thyroid Neoplasms/genetics , Thyroid Neoplasms/pathology , Vascular Endothelial Growth Factor Receptor-2/genetics , Vascular Endothelial Growth Factor Receptor-2/physiology , Young Adult
4.
Melanoma Res ; 16(2): 127-35, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16567968

ABSTRACT

Standard antineoplastic treatment for metastatic melanoma is ineffective in the large majority of patients. Therefore, alternative approaches need to be investigated. STI571 is a new antineoplastic compound, which selectively inhibits the tyrosine kinase activity of ABL, c-Kit and platelet-derived growth factor receptor (PDGFR). Melanoma may express all of these proteins. The aim of this study was to investigate whether STI571 inhibits the in-vitro growth of melanoma cells. Nineteen cell lines were obtained from four primary and 15 metastatic melanomas of cutaneous origin. The percentages of positive cells for the putative targets of STI571 were as follows: ABL, 41-100%; c-Kit, 8-97%; PDGFR-alpha, 41-98%; PDGFR-beta, 51-99%. 3-(4,5-Dimethylthiazol-yl)-2,5-diphenyltetrazolium (MTT) and viability assays showed that STI571 clearly inhibits the proliferation of eight of the 19 (42.1%) cell lines. No relationship could be established between the expression of c-Kit, ABL, PDGFR-alpha or PDGFR-beta and the response of cell lines to STI571. Our study shows, for the first time, an antiproliferative effect of STI571 on human melanoma cell lines of cutaneous origin, raising the possibility of the future clinical use of STI571. The identification of the target of STI571 in human cutaneous melanoma cells would allow the selection of patients who could benefit from this treatment.


Subject(s)
Antineoplastic Agents/pharmacology , Cell Proliferation/drug effects , Melanoma/metabolism , Piperazines/pharmacology , Pyrimidines/pharmacology , Benzamides , Blotting, Western , Cell Line, Tumor , DNA Mutational Analysis , Flow Cytometry , Humans , Imatinib Mesylate , Immunohistochemistry , Oncogene Proteins v-abl/metabolism , Polymerase Chain Reaction , Proto-Oncogene Proteins c-kit/metabolism , Receptor, Platelet-Derived Growth Factor alpha/metabolism
5.
Med Oral ; 9(1): 64-8, 2004.
Article in English, Spanish | MEDLINE | ID: mdl-14704619

ABSTRACT

We report a case of an intramandibular intraneural perineurioma developed in the left dentary nerve. This tumour is rare and shows a typical histological, immunohistochemical and ultrastructural appearance: concentric whorls of perineurial cells EMA+ and PS100- around nerve fibers. This tumour must be distinguished from extraneural or soft tissue perineurioma, also composed of perineurial cells, with distinct clinical presentation and histological appearance, and from localized hypertrophic neuropathy, a reactive process frequently identified with intraneural perineurioma. Cytogenetic evidence for the neoplastic nature of this tumour is also presented in this report.


Subject(s)
Mandibular Neoplasms/pathology , Nerve Sheath Neoplasms/pathology , Humans , Immunohistochemistry , Male , Mandibular Neoplasms/genetics , Middle Aged , Nerve Sheath Neoplasms/genetics
6.
Article in Es | IBECS | ID: ibc-29411

ABSTRACT

Presentamos el caso de un perineurioma intraneural del nervio dentario, de localización intramandibular. Se trata de un tumor poco frecuente del que se ha discutido su origen neoplásico o reactivo: La localización intraósea en región de cabeza y cuello es excepcional. Definimos las características histológicas e inmunohistoquímicas de este tumor, estableciendo el diagnóstico diferencial con la variedad extraneural de perineurioma, con otros tumores de la vaina del nervio periférico más frecuentes en esta localización y con la neuropatía hipertrófica localizada, entidad reactiva con la cual se ha identificado a veces. Mediante la hibridización in situ con inmunofluorescencia se confirma el origen neoplásico del perineurioma (AU)


Subject(s)
Middle Aged , Male , Humans , Immunohistochemistry , Nerve Sheath Neoplasms , Mandibular Neoplasms
SELECTION OF CITATIONS
SEARCH DETAIL
...